Journal article · 2011 · Open access
Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective
Current Oncology, 18(12), 20–27 · Published 1 October 2011 · DOI 10.3747/co.v18i0.939
In brief
“Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective” is a 2011 journal article by Amit M. Oza and 22 co-authors, published in Current Oncology. OpenAlex counts 41 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at Current Oncology.
- Citations
- 41
- Most cited in
- 2018 (5)
- Field-weighted impact
- 1.51
- References
- 33
- Authors
- 23
Abstract
Ovarian cancer is leading cause of gynecologic cancer mortality in Canada. To date, overall survival (os) has been the most-used endpoint in oncology trials because of its relevance and objectivity. However, as a result of various factors, including the pattern of sequential salvage therapies, measurement of os and collection of os data are becoming particularly challenging. Phase ii and iii trials have therefore adopted progression-free survival (pfs) as a more convenient surrogate endpoint; however, the clinical significance of pfs remains unclear. This position paper presents discussion topics and findings from a pan-Canadian meeting of experts that set out to evaluate the relevance of pfs as a valid endpoint in ovarian cancer;reach a Canadian consensus on the relevance of pfs in ovarian cancer; andtry to address how pfs translates into clinical benefit in ovarian cancer.Overall, the findings and the group consensus posit that future studies should ensure that trials are designed to evaluate pfs, os, and other clinically relevant endpoints such as disease-related symptoms or quality of life;incorporate interim futility analyses intended to stop accrual early when the experimental regimen is not active;stop trials early to declare superiority only when compelling evidence suggests that a new treatment provides benefit for a pre-specified, clinically relevant endpoint such as os or symptom relief; anddiscourage early release of secondary endpoint results when such a release might increase the frequency of crossover to the experimental intervention.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Oza, A. M., Castonguay, V., Tsoref, D., Díaz-Padilla, I., Karakasis, K., MacKay, H. J., Welch, S. A., Weberpals, J. I., Hoskins, P. J., Plante, M., Provencher, D. M., Tonkin, K. S., Covens, A. L., Ghatage, P., Gregoire, J., Hirte, H. W., Miller, D. M., Rosen, B. P., Maroun, J. A., . . . Stuart, G. C. (2011). Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective. Current Oncology, 18(12), 20–27. https://doi.org/10.3747/co.v18i0.939
MLA 9
Oza, Amit M., et al. “Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective.” Current Oncology, vol. 18, no. 12, 2011, pp. 20–27. https://doi.org/10.3747/co.v18i0.939.
Chicago
Oza, Amit M., Vincent Castonguay, Daliah Tsoref, Iván Díaz-Padilla, Katherine Karakasis, Helen J MacKay, Stephen A. Welch, et al. 2011. “Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective.” Current Oncology 18 (12): 20–27. https://doi.org/10.3747/co.v18i0.939.
Harvard
Oza, A. M. et al. (2011) ‘Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective’, Current Oncology, 18(12), pp. 20–27. doi:10.3747/co.v18i0.939.
IEEE
A. M. Oza et al., “Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective,” Current Oncology, vol. 18, no. 12, pp. 20–27, 2011, doi: 10.3747/co.v18i0.939.
BibTeX
@article{oza2011progression,
title = {{Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective}},
author = {Oza, Amit M. and Castonguay, Vincent and Tsoref, Daliah and Díaz-Padilla, Iván and Karakasis, Katherine and MacKay, Helen J and Welch, Stephen A. and Weberpals, Johanne Ingrid and Hoskins, Paul J and Plante, Marie and Provencher, Diane Michele and Tonkin, Katia Sonia and Covens, Allan L. and Ghatage, Prafull and Gregoire, J. and Hirte, Hal W. and Miller, Dianne M. and Rosen, Barry P. and Maroun, Jean Alfred and Buyse, Marc E and Coens, Corneel and Brady, Mark F. and Stuart, Gavin C.E.},
journal = {Current Oncology},
year = {2011},
volume = {18},
number = {12},
pages = {20--27},
doi = {10.3747/co.v18i0.939},
url = {https://doi.org/10.3747/co.v18i0.939}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2016 | 4 | |
| 2017 | 3 | |
| 2018 | 5 | |
| 2019 | 1 | |
| 2020 | 2 | |
| 2021 | 3 | |
| 2023 | 4 | |
| 2024 | 3 | |
| 2025 | 2 | |
| 2026 | 2 |
Its field-weighted citation impact is 1.51: it has been cited 1.51 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- ovarian cancer
- progression-free survival
- surrogate endpoints
- overall survival
- clinical trial endpoints
- early trial termination
- quality of life
- clinical benefit
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Oza, A. M., Castonguay, V., Tsoref, D., Díaz-Padilla, I., Karakasis, K., MacKay, H. J., Welch, S. A., Weberpals, J. I., Hoskins, P. J., Plante, M., Provencher, D. M., Tonkin, K. S., Covens, A. L., Ghatage, P., Gregoire, J., Hirte, H. W., Miller, D. M., Rosen, B. P., Maroun, J. A., . . . Stuart, G. C. (2011). Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective. Current Oncology, 18(12), 20–27. https://doi.org/10.3747/co.v18i0.939
How many times has this paper been cited?
41 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Current Oncology: sign in and open the PDF from this page.
Who wrote this paper?
Amit M. Oza, Vincent Castonguay, Daliah Tsoref, Iván Díaz-Padilla, Katherine Karakasis, Helen J MacKay, Stephen A. Welch, Johanne Ingrid Weberpals, Paul J Hoskins, Marie Plante, Diane Michele Provencher, Katia Sonia Tonkin and 11 more.
What is the DOI of this paper?
10.3747/co.v18i0.939, permanently at https://doi.org/10.3747/co.v18i0.939. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.